熱門資訊> 正文

默克KGaA获得欧盟认可埃兹梅克利

2025-07-19 01:02

Merck KGaA (NYSE:MRK) said that the European Commission approved Ezmekly for treating symptomatic, inoperable plexiform neurofibromas in patients with neurofibromatosis type 1 who are 2 years old and older.
The approval was given to SpringWorks Therapeutics, a healthcare company associated with Merck.

More on Merck

Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript
Why Merck Is A Better Dividend Stock Than Gilead Sciences
Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue
Bristol Myers fails in late-stage trial for Merck-partnered anemia therapy in blood cancer
Trump eyes drug, chip tariffs by month-end

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。